{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:41:44Z","timestamp":1773319304319,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Republic of Serbia Ministry of Education Science and Technological Development","doi-asserted-by":"publisher","award":["451\\u201303\\u2013137\/2025\\u201303\/200113"],"award-info":[{"award-number":["451\\u201303\\u2013137\/2025\\u201303\/200113"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.compbiolchem.2025.108732","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:08:47Z","timestamp":1761185327000},"page":"108732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Design and evaluation of dual c-Met\/\u03b2-tubulin inhibitors for triple-negative breast cancer: An In Silico approach"],"prefix":"10.1016","volume":"120","author":[{"given":"Milica","family":"Mihajlovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Coni\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Cvetanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-4117","authenticated-orcid":false,"given":"Ivan","family":"Petkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ljubomir","family":"Dini\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Dini\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9291-6654","authenticated-orcid":false,"given":"Aleksandar M.","family":"Veselinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.compbiolchem.2025.108732_bib1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2174\/1389557520666200429102334","article-title":"Applications of quantitative structure\u2013activity relationships (QSAR) based virtual screening in drug design: a review","volume":"20","author":"Achary","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108732_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097622","article-title":"Olive phenolics as c-Met inhibitors: (\u2212)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models","volume":"9","author":"Akl","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.compbiolchem.2025.108732_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2025.108732_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4939-9752-7_10","article-title":"Molegro virtual docker for docking","volume":"2053","author":"Bitencourt-Ferreira","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108732_bib5","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10637-020-00937-y","article-title":"Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, cpd a","volume":"38","author":"Breen","year":"2020","journal-title":"Invest. N. Drugs"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00125480-200201000-00001","article-title":"Gene-expression profiles in hereditary breast cancer","volume":"9","author":"Chinnaiyan","year":"2002","journal-title":"Adv. Anat. Pathol."},{"issue":"6178","key":"10.1016\/j.compbiolchem.2025.108732_bib7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1126\/science.1251827","article-title":"Two decades after BRCA: setting paradigms in personalized cancer care and prevention","volume":"343","author":"Couch","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.compbiolchem.2025.108732_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiolchem.2025.108732_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129171","article-title":"Target identification by structure-based computational approaches: recent advances and perspectives","volume":"83","author":"De Vita","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"15 Pt 1","key":"10.1016\/j.compbiolchem.2025.108732_bib10","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12885-018-4029-y","article-title":"Prevalence of pathogenic BRCA1\/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history","volume":"18","author":"Engel","year":"2018","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.compbiolchem.2025.108732_bib12","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.compbiolchem.2025.108732_bib13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1517\/14728222.2014.938050","article-title":"c-MET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?","volume":"18","author":"Gaule","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.compbiolchem.2025.108732_bib14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/cancers11040548","article-title":"Dasatinib treatment increases sensitivity to c-Met inhibition in triple-negative breast cancer cells","volume":"11","author":"Gaule","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.compbiolchem.2025.108732_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-4939-7899-1_3","article-title":"QSAR: what else?","volume":"1800","author":"Gini","year":"2018","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"10.1016\/j.compbiolchem.2025.108732_bib16","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1245\/s10434-013-3205-1","article-title":"Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort","volume":"20","author":"Greenup","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26279-8","article-title":"Quantitative structure\u2013activity relationship modeling for prediction of inhibition potencies of imatinib derivatives using SMILES attributes","volume":"12","author":"Hamzehali","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-015-0547-6","article-title":"The clinical and functional significance of c-Met in breast cancer: a review","volume":"17","author":"Ho-Yen","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.compbiolchem.2025.108732_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1498391","article-title":"c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity","volume":"15","author":"Jabbarzadeh Kaboli","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.compbiolchem.2025.108732_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138807","article-title":"Machine learning-based QSAR modeling, molecular docking, and dynamics simulation studies for cytotoxicity prediction in MDA-MB231 triple-negative breast cancer cell line","volume":"1315","author":"Khan","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.compbiolchem.2025.108732_bib21","first-page":"30","article-title":"Anti-proliferative and anti-migratory effects of EGFR and c-Met tyrosine kinase inhibitors in triple negative breast cancer cells","volume":"4","author":"Lefebvre","year":"2021","journal-title":"Prec. Cancer Med."},{"issue":"7","key":"10.1016\/j.compbiolchem.2025.108732_bib22","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest"},{"issue":"11","key":"10.1016\/j.compbiolchem.2025.108732_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cac2.12207","article-title":"Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020","volume":"41","author":"Lei","year":"2021","journal-title":"Cancer Commun."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108732_bib24","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/molecules25061375","article-title":"A review on applications of computational methods in drug screening and design","volume":"25","author":"Lin","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.compbiolchem.2025.108732_bib25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/1871520616666160502122724","article-title":"Breast cancer: current molecular therapeutic targets and new players","volume":"17","author":"Nagini","year":"2017","journal-title":"Anticancer Agents Med. Chem."},{"issue":"7","key":"10.1016\/j.compbiolchem.2025.108732_bib26","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13058-020-01349-9","article-title":"Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study","volume":"22","author":"O'Shaughnessy","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108732_bib28","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/ci700157b","article-title":"Y-randomization and its variants in QSPR\/QSAR","volume":"47","author":"R\u00fccker","year":"2007","journal-title":"J. Chem. Inf. Model"},{"issue":"6","key":"10.1016\/j.compbiolchem.2025.108732_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006192","article-title":"Systems modelling of the EGFR\u2013PYK2\u2013c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer","volume":"14","author":"Shin","year":"2018","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.compbiolchem.2025.108732_bib30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00044-017-1792-2","article-title":"QSAR study of dipeptidyl peptidase-4 inhibitors based on the Monte Carlo method","volume":"26","author":"Sokolovi\u0107","year":"2017","journal-title":"Med. Chem. Res."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejps.2012.04.012","article-title":"Chemoinformatics in anti-cancer chemotherapy: multi-target QSAR model for the in silico discovery of anti-breast cancer agents","volume":"47","author":"Speck-Planche","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.compbiolchem.2025.108732_bib32","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.compbiolchem.2025.108732_bib33","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1002\/etc.3466","article-title":"Monte Carlo-based quantitative structure\u2013activity relationship models for toxicity of organic chemicals to daphnia magna","volume":"35","author":"Toropova","year":"2016","journal-title":"Environ. Toxicol. Chem."},{"key":"10.1016\/j.compbiolchem.2025.108732_bib34","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.scitotenv.2017.01.198","article-title":"The index of ideality of correlation: a criterion of predictability of QSAR models for skin permeability?","volume":"586","author":"Toropova","year":"2017","journal-title":"Sci. Total Environ."},{"key":"10.1016\/j.compbiolchem.2025.108732_bib35","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/app15031206","article-title":"A (comprehensive) review of the application of quantitative structure\u2013activity relationship (QSAR) in the prediction of new compounds with anti-breast cancer activity","volume":"15","author":"Vasilev","year":"2025","journal-title":"Appl. Sci."},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijpharm.2015.08.078","article-title":"In silico prediction of the \u03b2-cyclodextrin complexation based on Monte Carlo method","volume":"495","author":"Veselinovi\u0107","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"18","key":"10.1016\/j.compbiolchem.2025.108732_bib37","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.2174\/1568026615666150506151533","article-title":"Application of SMILES notation-based optimal descriptors in drug discovery and design","volume":"15","author":"Veselinovi\u0107","year":"2015","journal-title":"Curr. Top. Med. Chem."},{"issue":"12","key":"10.1016\/j.compbiolchem.2025.108732_bib38","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1517\/17460441.2015.1083006","article-title":"Quantitative structure\u2013activity relationship: promising advances in drug discovery platforms","volume":"10","author":"Wang","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"issue":"W1","key":"10.1016\/j.compbiolchem.2025.108732_bib39","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1093\/nar\/gkab255","article-title":"ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties","volume":"49","author":"Xiong","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.compbiolchem.2025.108732_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.compbiolchem.2025.108732_bib41","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/bjc.2013.31","article-title":"High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer","volume":"108","author":"Zagouri","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.compbiolchem.2025.108732_bib42","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2174\/1389557520666200212111428","article-title":"The application of the combination of Monte Carlo optimization method-based QSAR modeling and molecular docking in drug design and development","volume":"20","author":"\u017divkovi\u0107","year":"2020","journal-title":"Mini Rev. Med. Chem."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927125003937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927125003937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:00:42Z","timestamp":1773255642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476927125003937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["S1476927125003937"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108732","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and evaluation of dual c-Met\/\u03b2-tubulin inhibitors for triple-negative breast cancer: An In Silico approach","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2025.108732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108732"}}